Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Accumulated Expenses (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Accumulated Expenses for 12 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 71.56% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Sep 2025, down 71.56%, and an annual FY2024 reading of $6.3 million, up 215.85% over the prior year.
  • Accumulated Expenses was $2.0 million for Q3 2025 at Avalo Therapeutics, down from $6.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $17.6 million in Q2 2021 and bottomed at $327000.0 in Q1 2025.
  • Average Accumulated Expenses over 5 years is $6.7 million, with a median of $6.3 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses soared 611.9% in 2021, then crashed 88.64% in 2022.
  • Year by year, Accumulated Expenses stood at $2.0 million in 2021, then soared by 560.7% to $13.2 million in 2022, then tumbled by 84.86% to $2.0 million in 2023, then surged by 215.85% to $6.3 million in 2024, then plummeted by 68.34% to $2.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for AVTX at $2.0 million in Q3 2025, $6.5 million in Q2 2025, and $327000.0 in Q1 2025.